Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WYWei YangXTXiaoqiong TangFLFei Li

Discussion

Loading...

Member takes

Overview

Observational analysis showed 70% overall response rate in patients with r/r mantle cell lymphoma, suggesting BTK inhibitor may offer new treatment options.

Key Points

  • TT-01488 demonstrated a 70% overall response rate in relapsed/refractory mantle cell lymphoma patients, including 40% complete responses.
  • Pharmacokinetics data showed TT-01488 was quickly absorbed with a median elimination half-life of 15.6 hours.
  • This open-label phase 1 study involved assessment of adverse events following TT-01488 treatment in heavily pretreated patients.
  • Findings highlight TT-01488's potential clinical benefit for mantle cell lymphoma patients resistant to prior BTK inhibitors.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d481https://doi.org/10.1182/blood-2025-1824
View Full Paper
Ask AI
Bookmark
Share